MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 560.7 USD | +0.48% |
|
-0.58% | +21.11% |
| 17/05 | JPMorgan Adjusts McKesson Price Target to $656 From $589 | MT |
| 16/05 | McKesson Seeks Acquisitions | CI |
| Sales 2025 * | 358B 29,773B | Sales 2026 * | 386B 32,087B | Capitalization | 72.89B 6,059B |
|---|---|---|---|---|---|
| Net income 2025 * | 3.72B 309B | Net income 2026 * | 3.9B 324B | EV / Sales 2025 * | 0.2 x |
| Net cash position 2025 * | 320M 26.57B | Net cash position 2026 * | 2.66B 221B | EV / Sales 2026 * | 0.18 x |
| P/E ratio 2025 * |
19.2
x | P/E ratio 2026 * |
17.9
x | Employees | 48,000 |
| Yield 2025 * |
0.48% | Yield 2026 * |
0.52% | Free-Float | 46.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
More news
| 1 day | +0.48% | ||
| 1 week | -0.58% | ||
| Current month | +4.38% | ||
| 1 month | +3.21% | ||
| 3 months | +8.04% | ||
| 6 months | +21.40% | ||
| Current year | +21.11% |
1 week
548.81
564.22
1 month
518.27566.16
Current year
462.70566.16
1 year
373.28566.16
3 years
184.43566.16
5 years
112.60566.16
10 years
106.11566.16
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 01/12/01 |
| Director of Finance/CFO | 55 | 27/18/27 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 20/14/20 |
Webster Dunbar
BRD | Director/Board Member | 62 | 01/22/01 |
| Director/Board Member | 66 | 13/22/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.31% | 1,085 M€ | +8.85% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 560.7 | +0.48% | 512,352 |
| 23/24/23 | 558 | +0.12% | 695,190 |
| 22/24/22 | 557.4 | +0.90% | 743,931 |
| 21/24/21 | 552.4 | -2.06% | 876,849 |
Delayed Quote Nyse, May 25, 2024 at 01:30 am IST
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
03/06/2024
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
560.7
USD
Average target price
584.1
USD
Spread / Average Target
+4.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.11% | 72.89B | |
| -4.38% | 23.48B | |
| +4.65% | 8.67B | |
| +10.16% | 8.51B | |
| -22.99% | 7.71B | |
| +12.88% | 5.21B | |
| +1.58% | 4.23B | |
| +1.31% | 3.99B | |
| +10.84% | 4.08B | |
| +23.03% | 3.67B |
- Stock Market
- Equities
- MCK Stock
